In 2021, the US approved the first drug designed to treat the cause of Alzheimer's, but the European Union rejected it. Whether the drug can actually treat the chief symptoms of the disease will be a point of contention in 2022
In 2021, the US approved the first drug designed to treat the cause of Alzheimer's, but the European Union rejected it. Whether the drug can actually treat the chief symptoms of the disease will be a point of contention in 2022
Share this Article
Recommended